Oded Biran - Rosetta Genomics Insider

Rosetta Genomics Ltd -- USA Stock  

USD 0.9199  0.0199  2.21%

General Counsel

Mr. Oded Biran serves as General Counsel of the company, since November, 2011. Mr. Biran was an independent attorney between the years 20102011, after previously working for us as legal counsel between June and November 2010. Prior to that, Mr. Biran was an associate in the law offices of Sharon Raviv and Co., a boutique law firm specializing in technology and communications, between December 2009 and June 2010. During the years of 2008 and 2009, Mr. Biran was an associate in Raved Magriso, Benkel, Lahav and Co.s, where he practiced in the corporate and securities department, specializing in corporate, technology, IP and complex mergers and acquisitions transactions. During 20062007, Mr. Biran was an associate at Gabriel Reubinoff and Co.s Tel Aviv office where he coheaded the firms class action department
Age: 35  Executive Since 2011      
972 73 222 0700  http://www.rosettagenomics.com
Biran holds a L.L.B degree from the Hebrew University in Jerusalem and is a member of the Israeli Bar Association.

Management Efficiency

The company has return on total asset (ROA) of (60.19) % which means that it has lost $60.19 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (137.95) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 2.45 M in liabilities with Debt to Equity (D/E) ratio of 222.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Rosetta Genomics Ltd has Current Ratio of 2.05 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Found 14 records

EXECUTIVE Since

Ross TuboVericel Corporation
2014
Tien MDNantKwest Inc
N/A
Samuel WadsworthDimension Therapeutics Inc
2013
Shayla ForsterVBI Vaccines Inc
2015
FRCPC MDDel Mar Pharmaceuticals Inc
N/A
Sam WadsworthDimension Therapeutics Inc
N/A
Jacob GeorgeVascular Biogenics Ltd
2000
Ayelet HornVascular Biogenics Ltd
2007
Eric MDDimension Therapeutics Inc
N/A
Rishi GuptaDimension Therapeutics Inc
2015
Mary ThistleDimension Therapeutics Inc
2017
David ReckerVericel Corporation
2014
David AndersonVBI Vaccines Inc
2015
Eric CrombezDimension Therapeutics Inc
2014

Entity Summary

Rosetta Genomics Ltd. develops and commercializes microRNAbased and other molecular diagnostics. Rosetta Genomics Ltd (ROSG) is traded on Nasdaq Capital Markets in USA. It is located in ISRAEL and employs 77 people. Rosetta Genomics is listed under Pharmaceutical Products category by Fama And French industry classification.

Did you try this?

Run Portfolio Optimization Now
   

Portfolio Optimization

Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Hide  View All  Next  Launch Portfolio Optimization
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Rosetta Genomics Ltd to your portfolio

Top Management

Rosetta Genomics Leadership Team
David Sidransky, Director
Kenneth Berlin, CEO
Anne Fields, Executive
Joshua Rosensweig, Director
Dganit Bar, Executive, Ph.D
Brian Markison, Chairman
Douglas Sites, President
Tal YaronEldar, Director, MBA
Eti Meiri, President, Ph.D
E Wassman, Executive
Robert Wassman, Executive
Oded Biran, Executive
Roy Davis, Director
Yitzhak Peterburg, Director
Kevin Watson, Director
Ron Kalfus, CFO
Gerald Dogon, Director
Tali YaronEldar, Director, MBA
Doug Sites, EVP

Stock Performance

Rosetta Genomics Performance Indicators